Commercializing the next generation of metabolic therapeutics.
MitoVida is the commercialization platform for the metabolic therapeutics, delivery technologies, and scientific innovations developed by Dr. Ahmed El-Sakka—neurosurgeon, metabolic oncology researcher, and pioneer in nano-phytochemical drug delivery.
With ten market-validated products already generating revenue, MitoVida is translating decades of research into scalable consumer, practitioner, and future pharmaceutical opportunities.
- Decades
- Of Founder Research
- 3 Horizons
- Innovation Roadmap
- Lab→Bedside
- Translational Platform
Strategic Partnership Opportunities
MitoVida is opening a limited number of strategic relationships across manufacturing, distribution, licensing, research collaboration, and investment.
Unlike companies built around a single product, MitoVida provides access to a growing portfolio of formulations, delivery systems, intellectual property, and metabolic therapeutic technologies spanning multiple commercialization horizons.
We are seeking partners who can accelerate development, expand market access, support clinical validation, strengthen manufacturing capabilities, or provide strategic capital.
Areas of Collaboration
- Strategic Investment
- Manufacturing Partnerships
- Global Distribution
- Licensing & White Label Programs
- Clinical Research Collaborations
- Joint Venture Opportunities
Dr. Ahmed El-Sakka. The scientific engine behind the platform.
MitoVida exists to commercialize decades of work by a, highly specialized researcher. Dr. El-Sakka is a neurosurgeon, clinical biochemist, and metabolic oncology investigator whose formulations, protocols, and delivery systems form the intellectual backbone of every product, prototype, and pipeline program inside the company.
Dr. Ahmed El-Sakka, MD
Chief Science Officer (CSO)
Core Areas of Expertise
Neurosurgery & Clinical Neuro-Metabolism
Operating background combined with advanced clinical biochemistry — designing submolecular interventions for chronic disease at the cellular level.
Metabolic Oncology Research
Boston College research fellowship and long-standing collaboration with Prof. Thomas Seyfried on tumor energetics, glycolytic dependency, and ketogenic metabolic therapy.
Nano-Phytochemical Drug Delivery
Formulation work on nanoparticle, liposomal, and glycrosome delivery systems to enhance bioavailability and tissue targeting of therapeutic compounds.
Publications & Recognition
BMC Medicine — Clinical Consensus, Glioblastoma
Co-author of the global clinical consensus framework for Ketogenic Metabolic Therapy in Glioblastoma, alongside Prof. Thomas Seyfried (Boston College).
Frontiers in Nutrition — Landmark GBM Case
Lead author of the first documented case of confirmed GBM treated with combined KMT, modified standard of care, and HBOT — showing 24-month regression.
Best Researcher — Metabolic Health Summit
One of only two metabolic scientists awarded globally each year for contributions to metabolic medicine.
An innovation platform —
not a supplement company.
Modern chronic diseases — diabetes, neurodegeneration, immune dysfunction, metabolic syndrome, and cancer — share deeper biochemical roots: mitochondrial dysfunction, redox imbalance, impaired methylation, metal dysregulation, and disrupted energy metabolism. Conventional medicine treats them downstream.
MitoVida was built around a different thesis: that a single specialist research engine — operating across formulation, delivery systems, and metabolic therapeutics — can produce a continuous pipeline of commercializable innovations, beginning with nutraceuticals and extending into pharmaceutical-grade metabolic oncology. Five operating principles govern every asset that enters the platform.
Metabolic Pathway Targeting
Every formulation is engineered around a specific biochemical bottleneck — methylation, glucose regulation, metal overload, mitochondrial stress, neural injury, or radiation-associated oxidative burden.
Synergistic Molecular Design
Active compounds are combined on the basis of mechanism, pathway overlap, and pharmacodynamic logic — not the ingredient-stacking common to the nutraceutical industry.
Advanced Delivery Systems
Active vitamin forms, chelated minerals, and nanoparticle, lipid, liposomal, and glycrosome platforms designed to maximize absorption, tissue delivery, and intracellular availability.
Regulatory Intelligence
The first generation was deliberately positioned within nutraceutical pathways — fast to market, clinically validated, and building trust before entering pharmaceutical regulatory tracks.
Clinical Feedback Loop
A professional-network rollout is generating real-world clinical signal from practitioners and patients — directly informing the next generation of formulations and the therapeutic pipeline.
Today. Next. Future. One innovation platform, three horizons.
MitoVida is structured as a layered commercialization model: near-term revenue from the existing portfolio funds the launch of premium nano-delivery nutraceuticals, which in turn de-risk the development of a pharmaceutical-grade metabolic oncology platform. Every horizon shares the same founder, the same scientific engine, and the same translational thesis.
Horizon 01 · Today
Commercialized Metabolic Nutraceuticals
Ten pathway-oriented formulations are developed, manufactured, and selling — proof that the platform can take a founder-designed molecular concept from research to revenue. These products are the evidence layer, not the destination.
- Practitioner-network distribution and clinical signal capture
- Brand, digital strategy, and direct-to-consumer scale-up
- Manufacturing optimization and supply expansion
- Funding the next horizon of the platform
Horizon 02 · Next
Advanced Delivery & Nano-Phytochemical Systems
Bioavailability-enhanced delivery for curcumin, resveratrol, quercetin, berberine derivatives, sulforaphane, honokiol and others — using nanoparticle, lipid, liposomal, and glycrosome platforms. Formulation SOPs and prototypes are in hand; validation and IP filings come next.
- Nanoparticle characterization & particle size analysis
- Stability, dissolution, and encapsulation testing
- Comparative bioavailability & tissue uptake studies
- Pilot-scale production and pharmaceutical positioning
Horizon 03 · Future
Metabolic Oncology Therapeutic Platform
Repurposed off-label drugs combined with phytochemicals, metabolic modulators, and nanoparticle delivery — targeting tumor energetics, glycolytic dependency, ferroptosis vulnerability, epigenetic dysregulation, and standard-of-care sensitization. This is the long-horizon, high-value pharmaceutical opportunity.
- Preclinical in vitro & combination-index studies
- Mechanism-of-action and normal-cell toxicity profiling
- Animal model studies and PK/PD evaluation
- IP strategy, out-licensing, and clinical trial preparation
"MitoVida is not a supplement company. It is a metabolic therapeutics platform — positioned at the intersection of metabolic science, precision formulation, and advanced drug delivery, built to commercialize a continuous pipeline of founder-led innovation."
The first commercial expression of the platform.
These ten formulations are not the business — they are the proof that the platform works. Each one targets a common but undertreated metabolic pattern, designed with systems-biology logic and positioned within the nutraceutical category as a fast, regulated route to clinical signal, revenue, and trust ahead of the pharmaceutical pipeline.
Methylation & Homocysteine
Supports methylation balance and homocysteine regulation — foundational for DNA expression, neurotransmitter synthesis, and detoxification.
Glucose & Insulin Sensitivity
Pathway-oriented support for glucose disposal, insulin sensitivity, and protection of normal cellular energy pathways from glycolytic overload.
Nerve Function & Neuropathy
Targets peripheral nerve health, neuro-mitochondrial respiration, and cellular-level support for cognitive and nerve resilience.
Sleep, Circadian & Stress Axis
Supports sleep architecture, circadian rhythm, and resilience against stress-related sleep disruption.
Metal Metabolism & Detox
Iron/copper balance, metal dysregulation, and detoxification support — addressing an under-treated metabolic vulnerability.
Immune & Micronutrient Resilience
Foundational immune support targeting cellular resilience and the depletion patterns commonly seen in chronic disease.
Magnesium & Electrolyte Balance
Addresses magnesium deficiency and electrolyte imbalance, central to mitochondrial and neuromuscular function.
Radiation-Oxidative Stress Support
Designed to support patients dealing with radiation-associated oxidative stress and free-radical burden.
Urinary Tract & Bladder Microbiome
Targeted support for urinary tract health and the bladder microbiome — an under-served clinical category.
Sugar-Free Electrolyte & Hydration
Clean, sugar-free hydration support — practical, daily-use category that broadens commercial reach.
Partner with the
platform behind the pipeline.
MitoVida is opening a limited set of strategic relationships across investment, licensing, manufacturing, distribution, and research collaboration — built around the founder-led innovation engine. The opportunity is not a single product line; it is participation in a multi-horizon commercialization platform with market-validated revenue today and pharmaceutical-grade assets in development.
Partnership pathways
- Investment — growth capital across Horizons 1–3
- Licensing — formulation and delivery-system IP
- Manufacturing — scale-up of nutraceutical and nano-delivery lines
- Distribution — practitioner, retail, and international channels
- Research collaboration — preclinical and translational programs
- Technology commercialization — pharmaceutical out-licensing